Buscar
Mostrando ítems 11-20 de 179
Pharmacologic interaction between oxfendazole and triclabendazole: In vitro biotransformation and systemic exposure in sheep
(Academic Press Inc Elsevier Science, 2019-09)
The aim of the current work was to evaluate a potential pharmacokinetic interaction between the flukicide triclabendazole (TCBZ) and the broad-spectrum benzimidazole (BZD) anthelmintic oxfendazole (OFZ) in sheep. To this ...
Determinación de los residuos de triclabendazol en leche de vacas procedentes de dos centros de crianza de ganado destinadas a la producción de derivados lácteos en el departamento de Cajamarca, mediante HPLC-DAD
(Universidad Peruana Cayetano HerediaPE, 2021)
Perú es un país hiperendémico para la infección por Fasciola hepática. Triclabendazol (TCBZ) es la droga de elección para tremátodos hepáticos; aunque, en los últimos años se ha incrementado los casos de resistencia en ...
Evaluation of activity of triclabendazole against Taenia solium metacestode in naturally infected pigs
(Elsevier, 2015)
OBJECTIVE: To assess the efficacy of triclabendazole (TCBZ) in porcine cysticercosis. METHODS: Eighteen naturally infected cysticercosis pigs were divided into 3 groups of 6 individuals each. The first group was treated ...
Fasciolosis en niños de regiones endémicas del Norte Altiplánico de Departamento de La Paz, Bolivia, postintervención masiva con triclabendazol: diagnóstico, tratamiento, eficacia y seguimiento
(2015)
El presente estudio fue realizado en 535 niños en edad escolar (4 – 13 años)
seleccionados por conveniencia, en los Municipios de Batallas y Pucarani del
Departamento de La Paz, el cálculo ...
Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole
(Elsevier Science, 2012-02)
An in vivo study in the laboratory rat model has been carried out to monitor morphological changes in adult Fasciola hepatica over a 4-day period resulting from co-treatment with triclabendazole (TCBZ) and ketoconazole ...
A Multienzyme Response is involved in the Phenomenon of Fasciola hepatica Resistance to Triclabendazole
(OMICS, 2015-10)
The trematode Fasciola hepatica is the causative agent of a parasitic zoonosis known as fasciolosis, disease that affects humans and most species of domestic animals. Triclabendazole (TCBZ) is the most widely used ...
Determinación de resistencia antihelmíntica (Fasciola hepatica) en ovinos frente a Albendazol y Triclabendazol, La Paz - Bolivia
(Universidad Nacional Mayor de San Marcos. Facultad de Medicina Veterinaria, 2009)
Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica
(Springer, 2011-10)
A study has been carried out to investigate whether the action of triclabendazole (TCBZ) against Fasciola hepatica is altered by inhibition of drug metabolism. The cytochrome P450 (CYP 450) enzyme pathway was inhibited ...
Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica
(Springer, 2010-05)
A study has been carried out to investigate whether the action of triclabendazole (TCBZ) against Fasciola hepatica is altered by inhibition of drug metabolism. The flavin monooxygenase system (FMO) was inhibited using ...
Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
(Public Library of Science, 2018-12)
Triclabendazole is a poorly-water soluble (0.24 μg/mL) compound classified into the Class II/IV of the Biopharmaceutical Classification System. It is the drug of choice to treat fascioliasis, a neglected parasitic disease ...